These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35140497)

  • 1. The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in
    Wang Z; Zhang L; Xu W; Li J; Liu Y; Zeng X; Zhong M; Zhu Y
    J Inflamm Res; 2022; 15():649-667. PubMed ID: 35140497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics-based screening of key genes for transformation of tyrosine kinase inhibitor-resistant lung adenocarcinoma to small cell lung cancer.
    Zhang Y; Chen Q; Huang T; Zhu D; Lu Y
    Front Med (Lausanne); 2023; 10():1203461. PubMed ID: 37583423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of resistance mechanisms to EGFR-TKIs and establishment and validation of prognostic model.
    Yang Z; Li H; Dong T; Li G; Chen D; Li S; Wang Y; Pan Y; Lu T; Yang G; Zhang G; Cheng P; Wang X
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13773-13792. PubMed ID: 37532906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of the model for predicting prognosis by key genes regulating EGFR-TKI resistance.
    Zhuge J; Wang X; Li J; Wang T; Wang H; Yang M; Dong W; Gao Y
    Front Genet; 2022; 13():968376. PubMed ID: 36506325
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
    Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
    Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.
    Ding J; Leng Z; Gu H; Jing X; Song Y
    Front Oncol; 2023; 13():1153131. PubMed ID: 37361601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Key Genes and Signaling Pathways in Entrectinibresistant Non-small Cell Lung Cancer Using Bioinformatic Analysis and Experimental Verification.
    Chen X; Zhao X; Li D; Zha W
    Curr Med Chem; 2024 Aug; ():. PubMed ID: 39108112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of
    Zhang SL; Zhang CY; Chen YQ; Li YF; Xie Z; Zhang XC; Zhou Q; Zhong WZ; Huang J; Sun H; Zheng MY; Xiao FM; Yan HH; Lu DX; Lv ZY; Wu YL; Chen HJ; Yang JJ
    J Thorac Dis; 2023 Sep; 15(9):4620-4635. PubMed ID: 37868836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in
    Shaurova T; Zhang L; Goodrich DW; Hershberger PA
    Front Genet; 2020; 11():281. PubMed ID: 32292420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.
    Liu L; Wang C; Li S; Bai H; Wang J
    Transl Lung Cancer Res; 2021 Sep; 10(9):3823-3839. PubMed ID: 34733631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
    Wang W; Xia X; Chen K; Chen M; Meng Y; Lv D; Yang H
    Front Oncol; 2021; 11():665045. PubMed ID: 34168988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
    Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
    Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
    Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
    Front Oncol; 2020; 10():542007. PubMed ID: 33123465
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis.
    Zheng Y; Hao S; Xiang C; Han Y; Shang Y; Zhen Q; Zhao Y; Zhang M; Zhang Y
    Front Oncol; 2021; 11():592854. PubMed ID: 34178613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report.
    Fang G; Liu W; Shang Y; Huo R; Shi X; Wang Y; Li J
    Ann Transl Med; 2022 Jan; 10(2):115. PubMed ID: 35282065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.
    Yang F; Zhang S; Meng Q; Zhou F; Pan B; Liu F; Yu Y
    Pulm Pharmacol Ther; 2021 Apr; 67():102001. PubMed ID: 33582208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of lncRNA-miRNA-mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor.
    Wang T; Yang C; Li B; Xing Y; Huang J; Zhang Y; Bu S; Ge H
    Front Genet; 2021; 12():758591. PubMed ID: 34868237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.